IMMUCELL CORP (ICCC)
US4525253062 - Common Stock
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024
PORTLAND, Maine, April 09, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company...
ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023
PORTLAND, Maine, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company...
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023
Conference Call Scheduled for Wednesday, February 28, 2024 at 9:00 AM ET...
ImmuCell says total sale for year ended December falls 6% Y/Y (NASDAQ:ICCC)
ImmuCell (ICCC) reports a 6% decrease in total sales for 2023 due to lower production output but sees a 30% increase in sales for Q4.
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023
PORTLAND, Maine, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023
PORTLAND, Maine, Nov. 13, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2023.
ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023
PORTLAND, Maine, Oct. 05, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023
PORTLAND, Maine, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023
Conference Call Scheduled for Friday, August 11, 2023 at 9:00 AM ET...
ImmuCell preliminary Q2 revenue falls 9% Y/Y (NASDAQ:ICCC)
ImmuCell (ICCC) on Tuesday announced preliminary Q2 sales that fell from a year ago. Read more here.
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2023
PORTLAND, Maine, July 11, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company...
ImmuCell to delay resubmission of FDA application for Re-Tain (ICCC)
ImmuCell (ICCC) said it is delaying resubmission of its market application to the US Food and Drug Administration for its dairy cattle medication Re-Tain by one month. Read more here.
ImmuCell Announces Change in Timing of Anticipated FDA Submission
PORTLAND, Maine, June 28, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company...
ImmuCell Appoints Bryan K. Gathagan to Board of Directors
PORTLAND, Maine, June 21, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company...
ImmuCell expects to resume full production in H2 2023 (NASDAQ:ICCC)
ImmuCell (ICCC) said on Thursday that it expects improvement from the depth of contamination in January will allow it to resume full production for the second half of 2023 and...
ImmuCell Announces Approval of Principal Terms of a $3 Million Debt Facility
PORTLAND, Maine, June 15, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company...
ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
PORTLAND, Maine, May 16, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2023
PORTLAND, Maine, May 11, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2023
Conference Call Scheduled for Friday, May 12, 2023 at 9:00 AM ET...
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2023
PORTLAND, Maine, April 05, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company...
ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2022
PORTLAND, Maine, Feb. 21, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company...
ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2022
Conference Call Scheduled for Wednesday, February 22, 2023 at 9:00 AM ET...
ImmuCell Announces Preliminary, Unaudited Sales Results for the Year Ended December 31, 2022
PORTLAND, Maine, Jan. 09, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2022
PORTLAND, Maine, Nov. 21, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company...
ImmuCell Announces Preliminary, Unaudited Sales Results for Third Quarter of 2022
PORTLAND, Maine, Oct. 05, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company...
ImmuCell to Participate in the Lytham Partners Fall 2022 Investor Conference
PORTLAND, Maine, Sept. 14, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2022
Conference Call Scheduled for Friday, August 12, 2022 at 9:00 AM ET...
ImmuCell Receives Technical Section Incomplete Letter from FDA Pertaining to Re-Tain®
PORTLAND, Maine, July 27, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company...
ImmuCell Announces Preliminary, Unaudited Sales Results for Second Quarter of 2022
PORTLAND, Maine, July 07, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2022
Q1 2022 Product Sales Increased 46% over Q1 2021...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2022
Conference Call Scheduled for Friday, May 13, 2022 at 9:00 AM ET...
UPDATE -- Dr. Mark Wustenberg joins ImmuCell as Commercial Leader of Stakeholder Engagement
PORTLAND, Maine, May 05, 2022 (GLOBE NEWSWIRE) -- Certain immaterial corrections have been made to the second and fifth paragraphs. ImmuCell Corporation...
Dr. Mark Wustenberg joins ImmuCell as Commercial Leader of Stakeholder Engagement
PORTLAND, Maine, May 05, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that...